Examples of using Immediate-release in English and their translations into Finnish
{-}
-
Colloquial
-
Official
-
Medicine
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
demonstrated significantly reduced glucose values compared to insulin in the postprandial periods after immediate-release exenatide injection.
the incidence for these adverse reactions was similar for insulin- and immediate-release exenatide-treated patients.
About half of this 6%(3% of the total patients given immediate-release exenatide in the controlled studies), had no apparent glycaemic response to immediate-release exenatide.
In clinical studies comparing PROCYSBI to the immediate-release cysteamine bitartrate, one third of the patients exhibited very common GI disorders nausea, vomiting, abdominal pain.
These reactions have usually been mild and usually did not result in discontinuation of immediate-release exenatide.
The maximum daily dose is three 1.1-mg immediate-release tablets or one 3.15-mg prolonged-release tablet.
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-exenatide antibodies following treatment with immediate-release exenatide.
three times daily or conventional immediate-release tablets or injections,
Ingredients in the blue, immediate-release layer: maize starch,
Immediate-release tablets release the active substance immediately,
For comparable doses, Numient results in a levodopa peak concentration(Cmax) that is 30% that of immediate-release levodopa/carbidopa.
In some patients, the skin lesions on elbows regressed after immediate-release cysteamine dose reduction see section 4.4.
Paracetamol AUC, Cmax and tmax were not significantly changed when paracetamol was given 1 hour before immediate-release exenatide injection.
Immediate-release exenatide lowered HbA1c by 1.1% from a baseline of 8.3%
The 200 mg once daily Viramune immediate-release lead-in dosing regimen should not be continued beyond 28 days at which point in time an alternative treatment should be sought due to the possible risk of underexposure and resistance.
The European Medicines Agency has deferred the obligation to submit the results of studies with immediate-release exenatide in one
In study 1100.1526(TRANxITION) patients on Viramune 200 mg immediate-release twice daily treatment for at least 18 weeks were randomised to either receive Viramune 400 mg prolonged-release once daily(n=295) or remain on their Viramune immediate-release treatment n=148.
of the AUC0-24,ss and Cmin, ss measured when patients were dosed with Viramune immediate-release tablets.
VERxVE(study 1100.1486) is a phase 3 study in which treatment-naïve patients received Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily
ss measured when patients were dosed with Viramune 200 mg immediate-release tablets twice daily.